GastroenterologyNews.net

Gastroenterology Xagena

Search results for "Crohn's disease"

A Phase III study showed that patients with moderate to severely active Crohn's disease treated with Adalimumab ( Humira ) have seen continuing improvements in clinical response and clinical remissio ...


IBD ( inflammatory bowel diseases ) is a term referring to several chronic diseases that cause inflammation of the intestines, including ulcerative colitis and Crohn's disease. Symptoms for both con ...


A open-label study carried out by physicians at New York-Presbyterian Hospital / Weill Cornell Medical Center showed that there may be a new application for the antibiotic Rifaximin ( Xifaxan ) in tr ...


Infliximab is the first biologic to show efficacy in two inflammatory bowel diseases ( IBD ), Crohn's Disease and ulcerative colitis. Results from two Phase III trials presented at Digestive Diseas ...


Treatment with a recombinant form of a hematopoietic growth factor GM-CSF, Sargramostim ( Leukine ), significantly reduced symptom severity and improved quality of life after 56 days of daily drug i ...


The results from a double-blind, multicenter phase II trial of the investigational drug MLN02 in patients with ulcerative colitis showed that MLN02 was more effective than placebo for the induction of ...


ENCORE, the second Phase III induction trial of Tysabri ( Natalizumab ) for the treatment of moderately to severely active Crohn's disease in patients with evidence of active inflammation, met the pr ...


Most treatments for Crohn's, an autoimmune disorder, are geared to suppress the immune response, but a new study demonstrates that stimulating innate immunity also is effective at improving symptoms i ...


A single 400 mg injection of Cimzia ( Certolizumab pegol, CDP 870 ) every four weeks was effective in maintaining control of the signs and symptoms of Crohn's disease following induction therapy, acco ...


Natalizumab ( Tysabri ), a humanized monoclonal antibody against 4 integrin, inhibits leukocyte adhesion and migration into inflamed tissue. Two controlled trials have evaluated Natalizumab as ind ...


Two studies, published in the Clinical Gastroenterology and Hepatology, have showen that prescription painkillers are effective in easing the pain of patients with dormant inflammatory bowel disease ( ...


The results from a study showing patients with moderate to severely active Crohn's disease treated with Adalimumab ( Humira ) were more likely to maintain clinical remission through one year than pati ...


Researchers found evidence that suggests Crohn's disease is caused by a weak immune response. The study, published in The Lancet, also suggest that Sildenafil ( Viagra ) might help in the treatment o ...


A Phase III trial ( PRECiSE 1 ) data have demonstrated that when compared with placebo, a significantly greater proportion of moderate to severe Crohn's disease patients achieved clinical response wit ...


Combined immunosuppression therapy is more effective than conventional treatment using corticosteroids for inducing remission in and management of patients recently diagnosed with Crohn’s disease. Usi ...